CureVac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in…
Biotechnology
DE, Tübingen [HQ]
Ratios
6 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | -37.86 | -60.67 | 71.02 | -131.28 | -172.91 | -172.97 | |
| Profit Margin | -553.50 | -573.46 | -263.96 | -399.76 | -369.37 | -483.96 | |
| Operating Margin | -565.80 | -571.30 | -253.58 | -400.29 | -370.00 | -524.58 | |
|
EPS Growth
|
- - | -32.50 | -84.91 | -125.51 | 40.27 | 12.88 | |
| EPS EUR | -40.00 | -53.00 | -98.00 | -221.00 | -132.00 | -115.00 | |
| Return on Assets (ROA) | -56.69 | -76.46 | -8.54 | -35.55 | -28.94 | -32.30 | |
| Return on Equity (ROE) | -222.05 | 233.34 | -18.15 | -59.80 | -46.70 | -49.26 | |
| Return on Invested Capital (ROIC) | -225.81 | -273.06 | -16.63 | -57.36 | -43.34 | -49.43 | |
| Solvency | |||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 0.17 | 60.59 | 1.99 | 2.49 | 4.89 | 5.30 | |
| Debt/Equity | 0.68 | -184.92 | 4.23 | 4.20 | 7.89 | 8.09 | |
| Debt/EBITDA | 31.88 | -52.97 | 1,177.15 | 202.48 | 203.37 | 144.63 | |
|
Debt/Capitalization
|
0.67 | 217.76 | 4.06 | 4.03 | 7.31 | 7.48 | |
| Long-Term Debt/Capitalization | - - | 224.63 | 3.64 | 3.56 | 6.51 | 6.64 | |
| Interest Debt per Share EUR | - - | 0.43 | 0.39 | 0.21 | 0.24 | 0.20 | |
| Debt Growth | - - | - - | -61.99 | -3.97 | 45.67 | -0.54 | |
| Liquidity | |||||||
| Current Ratio | 259.76 | 203.57 | 561.28 | 262.77 | 373.84 | 256.66 | |
| Quick Ratio | 239.93 | 177.41 | 535.91 | 233.31 | 345.48 | 236.60 | |
| Cash Ratio | 76.00 | 109.25 | 534.12 | 226.83 | 317.36 | 215.92 | |
| Operating Cash Flow Ratio | -200 | -300 | 200 | -200 | -100 | -100 | |
| Turnover | |||||||
| Inventory Turnover | 601.29 | 451.56 | 97.54 | 424.14 | 766.99 | 579.08 | |
| Receivables Turnover | 187.68 | 98.47 | 2,683.86 | 556.58 | 170.96 | 146.59 | |
| Payables Turnover | 196.52 | 524.91 | 80.42 | 194.82 | 269.60 | 309.75 | |
|
Asset Turnover
|
10.24 | 13.33 | 3.24 | 8.89 | 7.84 | 6.67 | |
| Fixed Turnover | 28.29 | 26.08 | 46.66 | 51.39 | 27.89 | 18.88 | |
| Coverage | |||||||
| Interest Coverage | -26,481.45 | -6,814.93 | -561.02 | -3,987.84 | -6,729.35 | -11,079.89 | |
| Asset Coverage | - - | 100 | 4,100 | 2,700 | 1,600 | 1,400 | |
| Cash Flow Coverage (CFGR) | -34,152.07 | -109.87 | 1,736.31 | -2,537.48 | -679.98 | -627.32 | |
| EBITDA Coverage | -24,300 | -6,200 | -400 | -3,700 | -6,000 | -10,000 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -0.83 | -1.07 | -1.47 | -7.34 | -23.39 | -30.30 | |
|
Price/Earnings (P/E)
|
-12,040.17 | -9,328.74 | -6,793.58 | -1,363.18 | -427.56 | -330.06 | |
| Price/Earnings Growth (PEG) | - - | -287.04 | -80.01 | -10.86 | 10.62 | 25.63 | |
|
Price/Book (P/B)
|
26,735.45 | -21,767.43 | 1,232.70 | 815.19 | 199.67 | 162.57 | |
| Price/Tangible Book (P/TB) | 26,735.45 | -21,767.43 | 1,232.70 | 815.19 | 199.67 | 162.57 | |
| Price/Sales (P/S) | 66,642.33 | 53,496.18 | 17,931.99 | 5,449.47 | 1,579.29 | 1,597.36 | |
|
Price/Cash Flow (P/CF)
|
-11,574.06 | -10,713.63 | 1,678.54 | -765.54 | -372.06 | -320.55 | |
| Price/Free CF (P/FCF) | -9,655.80 | -9,393.26 | 1,845.85 | -651.83 | -280.64 | -265.78 | |
| Price/Operating CF (P/OCF) | -11,574.06 | -10,713.63 | 1,678.54 | -765.54 | -372.06 | -320.55 |